Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has $0.21 as EPS estimate for the period quarter ended 2016-12-31.
Seven days ago, $0.21 was reported as the EPS estimates while $0.21 was reported 30 days ago. $0.21 and $0.21 were reported as the EPS estimates 60 and 90 days ago respectively. The percentage change in EPS estimates from 7 days ago was given as 0%.
The last 7 days had Up and down EPS revisions of 0 and 0 respectively. The last 30 and 60 days had 0, 2 respectively as the number of up revisions of EPS while 2 and 2 were for the last 90 and 120 days.
2, 3, were the number of down revisions of EPS in the last 30 and 60 respectively. But 90 and 120 days were at 3 and 3 respectively.
In the last 18 days, the number of EPS revisions up were 1 while those of down were 4.
For the period ended 2, the mean EPS estimate immediately prior to the announcement of actual earnings is $0.21. This has been calculated with 6 EPS estimates in mind. The 2016-08-02 announcement revealed $0.18 as the actual EPS. $0.05 and 38.46% are the EPS surprise amount in per share dollar and percentage terms respectively. Prior to the announcement of actual earnings, $0.02 was given as the standard deviation of all EPS estimates.
Quarterly Sales Estimates
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has arithmetic mean of all Annual sales estimates of $58.922. That of the median of all Annual sales estimates is $58.655. For the fiscal year 2016, 4 analysts for this company calculate the estimate.
$60.97 and $57.41 are the highest and the lowest annual estimates respectively but $1.529 is the standard deviation of all Annual sales estimates.
4 are the number of analysts covering the stock who have increased their sales estimate over the past week while 4 have decreased. From the past week, the percentage change of the mean estimate is 0%.
Since one month ago, the number of analysts covering the stock who have increased and decreased their sales estimate are 4 and 4 respectively. -1.504% is the percentage change of the mean estimate from one month ago.
The number of analysts covering the stock who have increased their sales estimate within the period of three months are 4 while 4 have decreased. The percentage change of the mean estimate for the same period is -1.616%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...